Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

L.H. van der Helm, N.J.G.M. Veeger, M. van Marwijk Kooy, A. Beeker, O. de Weerdt, M. de Groot, C. Alhan, M. Hoogendoorn, L. Laterveer, A.A. van de Loosdrecht, J. Koedam, E. Vellenga, G. Huls

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)877-882
JournalLeukemia Research
Volume37
Issue number8
DOIs
Publication statusPublished - 2013

Cite this

van der Helm, L. H., Veeger, N. J. G. M., van Marwijk Kooy, M., Beeker, A., de Weerdt, O., de Groot, M., ... Huls, G. (2013). Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leukemia Research, 37(8), 877-882. https://doi.org/10.1016/j.leukres.2013.03.022